Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40445 CENTESSA PHARMACEUTICALS PLC (Exact name of registrant as specified in its charter) England and Wales 98- ...

Exhibit 99.1 Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024 • Company advancing pipeline of potential best-in-class orexin receptor 2 (OX2R) agonists – Initiated Phase 1 clinical study with ORX750 being developed for sleep-wake disorders; Safety and ef icacy data in acutely sleep-deprived healthy volunteers assessed using Maintenance of Wakefulness Test (MWT) on track for 2H of 2024 – Nominated ORX142 as development candidate; Currently in IND enabl ...

Company advancing pipeline of potential best-in-class orexin receptor 2 (OX2R) agonists Initiated Phase 1 clinical study with ORX750 being developed for sleep-wake disorders; Safety and efficacy data in acutely sleep-deprived healthy volunteers assessed using Maintenance of Wakefulness Test (MWT) on track for 2H of 2024 Nominated ORX142 as development candidate; Currently in IND enabling activities for select neurological, neurodegenerative, and psychiatric disorders with excessive daytime sleepiness (EDS) ...

While the consensus price target is highly sought after by investors, the ability and unbiasedness of analysts in setting price targets have long been questionable. And investors making investment decisions solely based on this tool would arguably do themselves a disservice. Here's What You May Not Know About Analysts' Price Targets According to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than ...

Executive Leadership Changes - John Crowley CPA has been appointed as the new Chief Financial Officer (CFO) of Centessa Pharmaceuticals, bringing over 20 years of global finance and operational experience in the life sciences industry [5][9] - Gregory Weinhoff MD MBA, the former CFO, has been appointed to the newly created role of Chief Business Officer (CBO), leveraging his extensive business development experience [5][6] - John Crowley's previous roles include CFO at Fusion Pharmaceuticals, Executive Vice President and CFO at Merus Inc, and senior corporate finance positions at Charles River Laboratories, Ironwood Pharmaceuticals, Vertex Pharmaceuticals, and Sunovion Pharmaceuticals [9] - Gregory Weinhoff has over 20 years of business development experience, including roles as CFO at Centessa and Axovant Sciences, and co-founder of Arvelle Therapeutics, which was acquired by Angelini Pharma in 2021 [3] Company Overview and Strategic Focus - Centessa Pharmaceuticals is a clinical-stage pharmaceutical company focused on discovering and developing transformational medicines for patients [7] - The company's most advanced programs include a hemophilia program, an orexin agonist program for narcolepsy and sleep-wake disorders, and an immuno-oncology program based on the LockBody® technology platform [7] - The company believes its programs have the potential to change current treatment paradigms and establish new standards of care [7] - Centessa has strengthened its leadership team to position the company for its next phase of growth, with a focus on advancing its clinical programs and maintaining a strong financial framework [1] Business Development and Financial Strategy - The appointment of John Crowley as CFO is expected to enhance the company's financial strategy, operations, and planning, given his deep technical knowledge and experience in the life sciences industry [1][9] - Gregory Weinhoff's new role as CBO will focus on leveraging his experience in developing strategic industry partnerships to bring transformative medicines to patients [6] - The company has emphasized the importance of business development and financial strategy as it transitions into its next chapter of growth [1][6]

Centessa Pharmaceuticals PLC Sponsored ADR (CNTA) has been beaten down lately with too much selling pressure. While the stock has lost 11% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier. Here is How to Spot Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This ...

BOSTON and LONDON, May 21, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences: Event: Jefferies Global Healthcare Conference Date: June 6, 2024 Location: NY, NY Fireside Chat: 1:00 PM ET Event: Goldman Sachs 45th Annual Global Healthcare Conference Date: June 11, 2024 Lo ...

BOSTON and LONDON, May 21, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences: Event: Jefferies Global Healthcare Conference Date: June 6, 2024 Location: NY, NY Fireside Chat: 1:00 PM ET Event: Goldman Sachs 45th Annual Global Healthcare Conference Date: June 11, 2024 Lo ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40445 CENTESSA PHARMACEUTICALS PLC (Exact name of registrant as specified in its charter) England and Wales 98 ...

Financial Performance - Centessa Pharmaceuticals reported a net loss of $38.0 million for Q1 2024, a decrease from a net loss of $50.7 million in Q1 2023, representing a 25% improvement year-over-year[12] - Research and development expenses were $22.7 million for Q1 2024, down from $32.8 million in Q1 2023, indicating a 31% reduction[12] - Total assets decreased from $360,246 million on December 31, 2023, to $328,171 million on March 31, 2024, a decline of approximately 8.9%[22] - Cash and cash equivalents decreased from $128,030 million to $118,218 million, a reduction of about 7.1%[22] - Total liabilities decreased from $124,002 million to $113,008 million, a decline of approximately 8.9%[22] - Long-term debt increased slightly from $75,700 million to $76,800 million, an increase of about 1.5%[22] - Total shareholders' equity decreased from $236,244 million to $215,163 million, a decline of approximately 8.9%[22] - Other liabilities decreased significantly from $48,302 million to $36,208 million, a reduction of about 25.1%[22] - Short-term investments decreased from $128,519 million to $111,959 million, a decline of approximately 12.9%[22] - Other assets decreased from $103,697 million to $97,994 million, a reduction of about 5.5%[22] Capital and Funding - The company completed a public offering of 12,390,254 American Depositary Shares at $9.25 per ADS, resulting in net proceeds of approximately $107.2 million[8] - Cash, cash equivalents, and short-term investments totaled $230.2 million as of March 31, 2024, which, combined with the recent offering, is expected to fund operations into mid-2026[12] - Centessa's strengthened balance sheet positions the company well to execute on its clinical plans through multiple data readouts[3] Clinical Development - The Phase 1 clinical trial of ORX750 for narcolepsy has been initiated, with proof-of-concept data expected in the second half of 2024[4] - The registrational studies for SerpinPC for hemophilia B are ongoing, with an interim analysis of the PRESent-2 study planned for later in 2024[4] - The Phase 1/2a study of LB101 for solid tumors is currently in progress[4] - The median all-bleed annualized bleeding rate (ABR) was reduced by 96% in the ongoing Phase 2a study of SerpinPC, demonstrating sustained long-term efficacy[8] - The company plans to share Part 1 data from the PRESent-2 study at a medical conference in late 2024 or early 2025[8] Strategic Outlook - The company continues to focus on optimizing its asset management strategy in response to the declining asset values[22] - Future outlook indicates a cautious approach to market expansion and potential new product development in the upcoming quarters[22]